Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) — Baltimore, Maryland

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) is a clinical research site located in Baltimore, Maryland, United States 21201.

Crixeo Health Trust Score: 57/100 (POOR). This profile has not yet been claimed by the site owner.

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 57/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010)?

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) has a Crixeo Trust Score of 57/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) conducted?

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) has 1 clinical trials on record, with 1 currently active. Their work covers Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma.

Is Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) accredited by Crixeo Health?

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.